Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa

Simple item page
dc.contributor.authorJaoko, Walter
dc.contributor.authorNakwagala, Frederick N.
dc.contributor.authorAnzala, Omu
dc.contributor.authorManyonyi, Gloria Omosa
dc.contributor.authorBirungi, Josephine
dc.contributor.authorNanvubya, Annet
dc.contributor.authorOgutu, Hilda
dc.contributor.authorWakasiaka, Sabina
dc.contributor.authorMatu, Lucy
dc.contributor.authorOdada, Jane
dc.contributor.authorKonde, Carol
dc.contributor.authorMugisha, Emmanuel
dc.contributor.authorMuluubya, Andrew
dc.contributor.authorKaleebu, Pontiano
dc.date.accessioned2023-04-19T18:20:59Z
dc.date.available2023-04-19T18:20:59Z
dc.date.issued2008
dc.description.abstractThe safety and immunogenicity of plasmid pTHr DNA, modified vaccinia virus Ankara (MVA) human immunodeficiency virus type 1 (HIV-1) vaccine candidates were evaluated in four Phase I clinical trials in Kenya and Uganda. Both vaccines, expressing HIV-1 subtype A gag p24/p17 and a string of CD8 T-cell epitopes (HIVA), were generally safe and well-tolerated. At the dosage levels and intervals tested, the percentage of vaccine recipients with HIV-1-specific cell-mediated immune responses, assessed by a validated ex vivo interferon gamma (IFN-γ) ELISPOT assay and Cytokine Flow Cytometry (CFC), did not significantly differ from placebo recipients. These trials demonstrated the feasibility of conducting high-quality Phase 1 trials in Africa.en_US
dc.identifier.citationJaoko, W., Nakwagala, F. N., Anzala, O., Manyonyi, G. O., Birungi, J., Nanvubya, A., ... & Kaleebu, P. (2008). Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine, 26(22), 2788-2795.https://doi.org/10.1016/j.vaccine.2008.02.071en_US
dc.identifier.issn0264-410X
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/8524
dc.language.isoenen_US
dc.publisherVaccineen_US
dc.subjectHumansen_US
dc.subjectmodified vaccinia virus Ankara (MVA)en_US
dc.subjectHIV-1 A vaccineen_US
dc.titleSafety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africaen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.pdf
Size:
397.46 KB
Format:
Adobe Portable Document Format
Description:
Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences